Morgan Lewis Advises Armada Acquisition Corp. III on Business Combination with Brains Bioceutical Corp.

PHILADELPHIA, November 5, 2026: Morgan Lewis is representing Armada Acquisition Corp. III (Nasdaq: AACI), a publicly traded special purpose acquisition company, and Brains Bioceutical Corp., an integrated life sciences and pharmaceutical company focused on active pharmaceutical ingredient (API) manufacturing and supply, pharmaceutical research, and drug development, in connection with their definitive business combination agreement.

Armada III is a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination. Brains Bioceutical Corp. is a pharmaceutical company combining an established EU-GMP manufacturing and regulatory platform with a portfolio of proprietary and partnered drug-development programs focused on cannabinoid-based therapeutics.

Morgan Lewis partners Todd Hentges, Tara McElhiney, and Rahul Patel and associates Lauren Hutton-Work, Blaine Milton, Christina Wlodarczyk, Reema Abuelrish, and Melissa Lucar are advising Armada III.

For more, read the announcement.